Address
Naritaweg 227-A
Amsterdam
North Holland
1043 CB Netherlands
Contact
Fatema Rafiqi+31(0) 20 215 35 35
frafiqi@accesstomedicinefoundation.org
Website
AMR Research Programme, the AMR Benchmark Report
The 2021 Antimicrobial Resistance Benchmark assesses and compares how pharmaceutical companies are tackling AMR. This independent report covers R&D, responsible manufacturing, access and stewardship.
Track the progress and gaps in their efforts of companies to keep medicines and vaccines available, despite the rise of drug resistance.
Technology:
Microorganisms:
Application:
Development stage:
- Antimicrobial stewardship
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
- Infection prevention
- Microbial diagnostics
Microorganisms:
- Bacteria
- Fungi
- Viruses
- Yeasts
- Parasites
Application:
- Human
- Environmental
- Veterinary
- AgriFood
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- NGO
- Company
- Academia
- Institute
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- UTI
- STI
- BSI
- RTI
- GII
- SSTI
- CNSI
- IAI
- SSI
Geographic origin:
- Eurasia
- North America
- South America
- Africa
- Oceania
The Foundation works with pharmaceutical companies to gather data to report on activities, initiatives and progress as relevant.
We stimulate and guide pharmaceutical companies to do more for vulnerable populations without access to medicine.
Short thematic reports to provide an assessment of the current state and recommendations to key stakeholders on next steps to curbing AMR.
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!